ScoreWhy is CytomX Therapeutics, Inc. ?
1
With a fall in Net Sales of -79.85%, the company declared Very Negative results in Mar 26
- The company has declared negative results for the last 3 consecutive quarters
- The company has declared negative results in Sep 25 after 3 consecutive negative quarters
- NET SALES(HY) At USD 10.92 MM has Grown at -87.73%
- PRE-TAX PROFIT(Q) At USD -18.19 MM has Fallen at -177.11%
- NET PROFIT(Q) At USD -18.25 MM has Fallen at -177.57%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 39.81%, its profits have fallen by -154.8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is CytomX Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
CytomX Therapeutics, Inc.
39.81%
0.87
93.49%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-5.36%
EBIT Growth (5y)
8.99%
EBIT to Interest (avg)
-30.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.98
Sales to Capital Employed (avg)
1.70
Tax Ratio
0.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
41.52%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.87
EV to EBIT
-37.58
EV to EBITDA
-40.04
EV to Capital Employed
-24.98
EV to Sales
11.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-17.64%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -80.09 MM
RAW MATERIAL COST(Y)
Fallen by 1.72% (YoY
-24What is not working for the Company
NET SALES(HY)
At USD 10.92 MM has Grown at -87.73%
PRE-TAX PROFIT(Q)
At USD -18.19 MM has Fallen at -177.11%
NET PROFIT(Q)
At USD -18.25 MM has Fallen at -177.57%
ROCE(HY)
Lowest at -34.29%
Here's what is working for CytomX Therapeutics, Inc.
Operating Cash Flow
Highest at USD -80.09 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Raw Material Cost
Fallen by 1.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for CytomX Therapeutics, Inc.
Net Sales
At USD 10.92 MM has Grown at -87.73%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -18.19 MM has Fallen at -177.11%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -18.25 MM has Fallen at -177.57%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
